SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-035373
Filing Date
2024-03-22
Accepted
2024-03-22 16:20:11
Documents
12
Period of Report
2024-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-20240319.htm   iXBRL 8-K 42257
2 EX-10.1 abio-ex10_1.htm EX-10.1 24763
  Complete submission text file 0000950170-24-035373.txt   184208

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT abio-20240319.xsd EX-101.SCH 24886
15 EXTRACTED XBRL INSTANCE DOCUMENT abio-20240319_htm.xml XML 4679
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 24775510
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)